ORIC's Rinzimetostat Shows 'Best-in-Disease' Potential, Advances to Phase 3 Trial
ORIC has more than doubled off its 52-week low of $4.52.
Summary
ORIC Pharmaceuticals reported Q1 2026 financial results and significant operational updates, primarily highlighting the advancement of its lead oncology candidate, rinzimetostat. The company selected the Recommended Phase 3 Dose (RP3D) for rinzimetostat in combination with darolutamide for the Himalayas-1 global Phase 3 trial in post-abiraterone mCRPC, expected to initiate in 1H 2026. Dose optimization data for rinzimetostat demonstrated a highly differentiated safety profile and landmark rPFS rates (93%, 84%, 84% at 3, 4, and 5 months) consistent with a competitor and superior to standard of care therapies. This strong clinical data supports a potential "best-in-disease" profile, significantly de-risking the program. Furthermore, ORIC reported a robust cash position of approximately $420 million, extending its runway into 2H 2028, well beyond the anticipated primary endpoint readout of the first Phase 3 trial. Investors will now watch for the initiation of the Himalayas-1 trial and further clinical updates for both rinzimetostat and enozertinib in the second half of 2026.
At the time of this announcement, ORIC was trading at $9.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $966.4M. The 52-week trading range was $4.52 to $14.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.